IL292889A - Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies - Google Patents

Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies

Info

Publication number
IL292889A
IL292889A IL292889A IL29288922A IL292889A IL 292889 A IL292889 A IL 292889A IL 292889 A IL292889 A IL 292889A IL 29288922 A IL29288922 A IL 29288922A IL 292889 A IL292889 A IL 292889A
Authority
IL
Israel
Prior art keywords
riu0003
wkhu0003
ruu0003
khu0003
dqu0003
Prior art date
Application number
IL292889A
Other languages
English (en)
Hebrew (he)
Inventor
Christine Morel Coquery
Jonathon Andrew Kluft
Iii William Thomas Symonds
Original Assignee
Immunovant Sciences Gmbh
Christine Morel Coquery
Jonathon Andrew Kluft
Iii William Thomas Symonds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovant Sciences Gmbh, Christine Morel Coquery, Jonathon Andrew Kluft, Iii William Thomas Symonds filed Critical Immunovant Sciences Gmbh
Publication of IL292889A publication Critical patent/IL292889A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL292889A 2019-11-19 2020-11-18 Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies IL292889A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
PCT/US2020/061028 WO2021101975A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Publications (1)

Publication Number Publication Date
IL292889A true IL292889A (en) 2022-07-01

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292889A IL292889A (en) 2019-11-19 2020-11-18 Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies

Country Status (11)

Country Link
US (1) US20230049011A1 (https=)
EP (1) EP4061486A1 (https=)
JP (1) JP7722991B2 (https=)
KR (1) KR20220100880A (https=)
CN (1) CN114728180A (https=)
AU (1) AU2020387399A1 (https=)
CA (1) CA3157797A1 (https=)
IL (1) IL292889A (https=)
MX (1) MX2022005862A (https=)
TW (1) TW202132346A (https=)
WO (1) WO2021101975A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
WO2024052357A1 (en) * 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Methods of treating graves' disease using anti-fcrn antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3137504T3 (pl) * 2014-04-30 2023-10-16 Hanall Biopharma Co., Ltd. Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
RS64768B1 (sr) * 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
EP3294335B1 (en) * 2015-05-12 2023-07-05 Syntimmune Inc. Humanized affinity matured anti-fcrn antibodies
SMT202400004T1 (it) * 2016-07-29 2024-03-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies

Also Published As

Publication number Publication date
JP2023502398A (ja) 2023-01-24
CA3157797A1 (en) 2021-05-27
KR20220100880A (ko) 2022-07-18
AU2020387399A1 (en) 2022-05-19
CN114728180A (zh) 2022-07-08
TW202132346A (zh) 2021-09-01
JP7722991B2 (ja) 2025-08-13
MX2022005862A (es) 2022-06-23
WO2021101975A1 (en) 2021-05-27
US20230049011A1 (en) 2023-02-16
EP4061486A1 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
IL292889A (en) Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies
Yoshihara et al. Nano-controlled molecular interaction at adhesive interfaces for hard tissue reconstruction
DE102008042212A1 (de) Reflektives optisches Element und Verfahren zu seiner Herstellung
Bosco et al. Hydroxyapatite nanocrystals functionalized with alendronate as bioactive components for bone implant coatings to decrease osteoclastic activity
IL275004B2 (en) Battery swapping station and control method therefor
US10105390B2 (en) Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles
WO2021259634A1 (de) Optisches element für eine euv-projektionsbelichtungsanlage
KR20110059546A (ko) 스트론튬 염，비타민 ｄ 및 시클로덱스트린을 포함하는 약제 조성물
JP3853785B2 (ja) 口腔用組成物
DE102020120884B4 (de) Verfahren und Vorrichtung zum Ätzen einer Lithographiemaske
EP3663264A1 (en) Method for producing zirconia particle-containing powder
Cunha-Filho et al. Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems
Adhikari et al. Optimization of methionine in inhalable High-dose Spray-dried amorphous composite particles using response surface Method, infrared and low frequency Raman spectroscopy
EP1603525A1 (en) Oral preparation system
CA2480125C (en) Use of carbon-2-modified-19-nor-vitamin d analogs to induce the formation of new bone
EP2773629B1 (en) Process for the preparation of an amorphous form of cabazitaxel
WO1999031112A1 (de) Vitamin d-derivate mit phosphoratomen in den seitenketten
Rosenqvist et al. Evaluating optimal combination of clodronate and bioactive glass for dental application
WO2022089885A1 (de) Optisches element, insbesondere zur reflexion von euv-strahlung, optische anordnung und verfahren zum herstellen eines optischen elements
IL276083B2 (en) Security door mounting arrangement
DE102022203644A1 (de) Verfahren zum Herstellen eines Substrats und eines reflektiven optischen Elements für die EUV-Lithographie
EP4284317B1 (en) A method for producing fluorapatite crystals
Pazos et al. [3, 3]-Sigmatropic rearrangement mediated synthesis of chiral building blocks for the preparation of Gemini and its analogs
IL292204B2 (en) A conveyor device for at least transferring a liquid and a pump comprising such a conveyor device
KR101375632B1 (ko) 과민감성 치아의 완화를 위한 치약 조성물